Advancing Antibody Discovery: Novel Platforms and Their Application to Infectious Disease and Autoimmune Targets

Loading...
Thumbnail Image

Journal Title

Journal ISSN

Volume Title

Publisher

Abstract

Antibody-based therapeutics and vaccines have transformed the prevention and treatment of a myriad of diseases. This dissertation focuses on the development and application of high-throughput discovery technologies towards the discovery of novel biologics for both endemic RNA viruses and autoimmune indications. First, we developed nbLIBRA-seq, a high-throughput single-cell technology for the rapid discovery of antigen-specific camelid heavy-chain antibodies. This platform enabled simultaneous screening against multiple antigens within a single experiment and was validated through the identification of functional nanobodies targeting human CD71, respiratory syncytial virus (RSV), and human metapneumovirus (hMPV). Together, these results established nbLIBRA-seq as a versatile platform for rapid nanobody discovery against any target of interest. Next, we mapped the human antibody repertoire against norovirus in healthy individuals. Our studies demonstrated that naturally acquired immunity generates both genotype-specific and broadly cross-reactive antibodies capable of recognizing diverse, clinically-important norovirus variants. Several antibodies inhibited histo-blood group antigen binding, a critical step in viral attachment, providing new insights into the mechanisms of naturally acquired protection and identifying promising candidates for therapeutic development and structure-guided vaccine design. Finally, we engineered a multivalent ferritin nanoparticle vaccine designed to co-display RSV and hMPV fusion glycoproteins to elicit broadly protective antibody responses. Although the engineered nanoparticles assembled successfully and retained key antigenic features, immunization studies revealed reduced immunogenicity relative to soluble antigens and failed to generate robust cross-reactive antibody responses. These findings identify important design considerations for future multivalent vaccine development. Collectively, this dissertation highlights the power of leveraging humoral immune responses to advance both fundamental immunological understanding and aid in the development of next-generation antibody-based therapeutics and vaccines. The studies presented here underscore the value of integrating antibody discovery technologies, alternate animal models and innovative vaccine modalities to address unmet medical needs. As emerging and endemic pathogens continue to challenge global health, continued innovation in therapeutic antibody discovery and vaccine development will be essential for translating our growing understanding of humoral biology into clinical interventions.

Description

Keywords

Immunology, Antibody, Virology, Immune Repertoire,

Citation

Endorsement

Review

Supplemented By

Referenced By